Company Profile

BIOCON LTD.

NSE : BIOCONBSE : 532523ISIN CODE : INE376G01013Industry : Pharmaceuticals & DrugsHouse : Private
BSE397.25-4.1 (-1.02 % )
PREV CLOSE (Rs.) 401.35
OPEN PRICE (Rs.) 405.70
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 60166
TODAY'S LOW / HIGH (Rs.)396.70 405.70
52 WK LOW / HIGH (Rs.)363.3 487.7
NSE397.55 -3.8 (-0.95 % )
PREV CLOSE(Rs.) 401.35
OPEN PRICE (Rs.) 402.90
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 397.55 (213 )
VOLUME 1824603
TODAY'S LOW / HIGH(Rs.) 396.60 404.95
52 WK LOW / HIGH (Rs.)363.25 487.75

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.00
TTM EPS (Rs.) 2.34
P/E Ratio 170.03
Book Value (Rs.) 64.70
Face Value (Rs.) 5
MCap (Rs. in Mn) 476938.35
Price/Earning (TTM) 124.20
Price/Sales (TTM) 23.51
Price/Book (MRQ) 6.14
PAT Margin (%) 20.19
ROCE (%) 7.62
Incorporation Year : 1978

Management Info :

Kiran Muzumdar Shaw - Chairman Siddharth Mittal - Managing Director

Registered Office :

Address : 20th Km,Hosur Road,Electronic City,
Bengaluru,
Karnataka-560100

Phone : 080 2808 2808

Website : www.biocon.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX
NEWS More
10Jun06-10-2021$Biocon informs about institutional investor meet Biocon informs about institu

Pursuant to Regulation 30 (6) of the SEBI LODR Regulations, 2015, Biocon has informed that a meeting was conducted with Institutional Investor / Research Analysts on 9th June 2021. Further details of the meeting are attached.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 30 (6) of the SEBI LODR Regulations, 201..
21May05-21-2021$Sebi imposes fine of Rs 14 lakh on Biocon, its designated person for violation of market norms Sebi imposes fine of Rs 14 l

Markets regulator Sebi has imposed a total fine of Rs 14 lakh on Biocon and its designated person for violation of market norms. Designated person of the firm, Narendra Chirmule, who was employed with the company as senior vice president-R&D is facing a fine of Rs 5 lakh for trading in the company's securities when the trading window was closed.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Markets regulator Sebi has imposed a total fine of Rs 14 lakh o..
21May05-21-2021$Biocon slips as Sebi imposes fine of Rs 14 lakh for violation of market norms Biocon slips as Sebi imposes

Biocon is currently trading at Rs. 383.35, down by 0.25 points or 0.07% from its previous closing of Rs. 383.60 on the BSE.

The scrip opened at Rs. 386.90 and has touched a high and low of Rs. 386.90 and Rs. 383.00 respectively. So far 51972 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 487.70 on 23-Dec-2020 and a 52 week low of Rs. 342.80 on 28-May-2020.

Last one week high and low of the scrip stood at Rs. 393.70 and Rs. 382.30 respectively. The current market cap of the company is Rs. 46067.02 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 23.44% and 15.89% respectively.

Markets regulator Sebi has imposed a total fine of Rs 14 lakh on Biocon and its designated person for violation of market norms. Designated person of the firm, Narendra Chirmule, who was employed with the company as senior vice president-R&D is facing a fine of Rs 5 lakh for trading in the company's securities when the trading window was closed.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon is currently trading at Rs. 383.35, down by 0.25 points..
19May05-19-2021$Biocon informs about investor presentation Biocon informs about investo
Biocon has informed that it enclosed Investor Presentation under regulation 30 of the SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015. The above information will also be available on the website of the Company at www.biocon.com.

The above information is a part of company’s filings submitted to BSE.

Biocon has informed that it enclosed Investor Presentation unde..
29Apr04-29-2021$Biocon jumps on reporting 92% rise in Q4 consolidated net profit Biocon jumps on reporting 92

Biocon is currently trading at Rs. 398.40, up by 7.45 points or 1.91% from its previous closing of Rs. 390.95 on the BSE.

The scrip opened at Rs. 387.20 and has touched a high and low of Rs. 402.10 and Rs. 386.00 respectively. So far 517268 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 487.70 on 23-Dec-2020 and a 52 week low of Rs. 320.90 on 15-May-2020.

Last one week high and low of the scrip stood at Rs. 403.30 and Rs. 386.00 respectively. The current market cap of the company is Rs. 47640.00 crore.

The promoters holding in the company stood at 60.67%, while Institutions and Non-Institutions held 23.44% and 15.89% respectively.

Biocon has reported results for fourth quarter and year ended March 31, 2021.

The company has reported a fall of 33.76% in its net profit at Rs 67.70 crore for the quarter under review as compared to Rs 102.20 crore for the same quarter in the previous year. Total income of the company decreased by 2.38% at Rs 536.50 crore for Q4FY21 as compared Rs 549.60 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported a rise of 92.34% in its net profit attributed to the shareholders from continuing operations at Rs 253.50 crore for the quarter under review as compared to Rs 131.80 crore for the same quarter in the previous year. Total income of the company increased by 26.13% at Rs 2044.10 crore for Q4FY21 as compared Rs 1620.60 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported a fall of 36.38% in its net profit at Rs 280.50 crore as compared to Rs 440.90 crore for the previous year. Total income of the company decreased by 0.53% at Rs 2178.60 crore for year under review as compared to Rs 2190.10 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported a fall of 3.46% in its net profit attributed to the shareholders from continuing operations at Rs 750.20 crore as compared to Rs 777.10 crore for the previous year. However, total income of the company increased by 13.90% at Rs 7360.30 crore for year under review as compared to Rs 6461.90 crore for year ended March 31, 2020.

Biocon is currently trading at Rs. 398.40, up by 7.45 points or..
Financials More
Rs. in Millions
QTR Mar 21 ANNUAL 21
Net Profit6772805
Gross Profit 863 3588
Operating Profit 11184627
Net Sales 491620284
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Pfizer (BSE)
 5586.35 (1.67%)
M.Cap ( in Cr)
25524.72
Sanofi India (BSE)
 7735.00 (0.53%)
M.Cap ( in Cr)
17814.19
Glaxosmithkline Phar (BSE)
 1531.25 (1.30%)
M.Cap ( in Cr)
25940.30
Medicamen Biotech (BSE)
 550.05 (3.61%)
M.Cap ( in Cr)
671.97
JB Chem & Pharma (BSE)
 1545.00 (1.12%)
M.Cap ( in Cr)
11940.08
Shareholding Pattern More
PROMOTERS 60.67 %
FI/BANKS/INSURANCE 4.13 %
MUTUAL FUNDS/UTI 2.51 %
NON-INSTITUTION 15.89 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes